Abhijeet Lokras

Abhijeet Lokras
University of Copenhagen · Department of Pharmacy

9.11
 · 
Master of Pharmacy

About

4
Publications
3,405
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
8
Citations
Introduction
I am currently a PhD student in Vaccine Design and Delivery Group at the University of Copenhagen. My research focus is on quality-by-design based development, optimization, and extensive physicochemical characterization of non-viral, lipid-mediated delivery of nucleic acids, specifically mRNA based vaccines to tumour cells. The delivery platform is based on cationic lipids along with a polymer which will be manufactured as nanoparticles using microfluidics.
Research Experience
December 2019 - December 2019
University of Copenhagen
Position
  • Research Assistant
May 2018 - August 2019
University of Copenhagen
Position
  • Master Thesis Student
Education
September 2017 - September 2019
University of Copenhagen
Field of study
  • Drug Development
August 2014 - August 2016
Bombay College of Pharmacy
Field of study
  • Pharmacology

Publications

Publications (4)
Article
Aim To investigate comparative in vitro and in vivo performance of lipid vesicular and particulate systems in escalating oral bioavailability for superior hepatoprotection. Materials and Methods Systems were fabricated using easy to scale up process and novel excipients to deliver Silibinin. In vitro characterization followed by pharmacokinetic an...
Article
Full-text available
In the past few years, there has been increasing focus on the use of messenger RNA (mRNA) as a new therapeutic modality. Current clinical efforts encompassing mRNA-based drugs are directed toward infectious disease vaccines, cancer immunotherapies, therapeutic protein replacement therapies, and treatment of genetic diseases. However, challenges tha...
Article
Background With the recent approval of the first small interfering RNA (siRNA) therapeutic formulated as nanoparticles, there is increased incentive for establishing the factors of importance for the design of stable solid dosage forms of such complex nanomedicines. Methods The aims of this study were: (i) to identify factors of importance for the...
Article
Full-text available
Background Antisense oligonucleotides (ASOs) are promising therapeutics for specific modulation of cellular RNA function. However, ASO efficacy is compromised by inefficient intracellular delivery. Lipid-polymer hybrid nanoparticles (LPNs) are attractive mediators of intracellular ASO delivery due to favorable colloidal stability and sustained rele...

Questions and Answers

Question & Answers (13)
Question
Hi,
I have been using the KSV Langmuir Trough and LayerBuilder for a long time now. Recently, we had to move the instrument due to renovations and I thought of calibrating it once again. We followed exactly all the procedures that are recommended in the manual, taking utmost care at every step. The supplied calibrated weight (metal disc) was measured on a sensitive analytical balance (258.82 mg) and used for calibration of the electrobalance. However, after calibration, the weight difference is almost 2.38 mg. When I zero the balance and measure the weight of the supplied calibrated weight, it shows as 261.20 mg in the Manual Control window instead of 258.82 mg.
For those who have worked with this instrument, can you provide me with any details on how you tackled this issue?
Also, do you think a 0.91% error in the weight is quite a lot for surface pressure measurements if we are running controls, i.e. blank buffer solution and comparing different surfactants, rather than absolute quantification of single independent surfactant?
Thank you.
Question
I am reviewing the history of Eptifibatide and came across this line in one of the chemistry reviews by FDA. How can it exceed 100% ?

Network

Cited By